Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 5/20 | 0.46 |
| ▸ | CES1 | P23141 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.42 |
| ▸ | PPARG | P37231 | 6/20 | 0.42 |
| ▸ | PPARD | Q03181 | 6/20 | 0.42 |
| ▸ | PPARA | Q07869 | 6/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28210581 | 0.98 | CES2 (0.48) | CES2CES1HSD17B10GMNNTP53 | |
| SCHEMBL3874809 | 0.92 | NOS3 (0.46) | CES2CES1HSD17B10TP53AKR1B1 | |
| SCHEMBL11546204 | 0.91 | CES2 (0.44) | CES2CES1HSD17B10GMNNTP53 | |
| SCHEMBL11545742 | 0.91 | CES2 (0.44) | CES2CES1HSD17B10GMNNTP53 | |
| SCHEMBL11140046 | 0.90 | CES2 (0.50) | CES2CES1HSD17B10GMNNTP53 | |
| SCHEMBL14478084 | 0.88 | CES2 (0.54) | CES2CES1HSD17B10GPR84PPARG | |
| SCHEMBL14166641 | 0.88 | CES2 (0.54) | CES2CES1HSD17B10GPR84PPARG | |
| SCHEMBL14478082 | 0.88 | CES2 (0.54) | CES2CES1HSD17B10GPR84PPARG | |
| SCHEMBL14166455 | 0.88 | CES2 (0.48) | CES2CES1HSD17B10GMNNTP53 | |
| SCHEMBL11344208 | 0.88 | CES2 (0.54) | CES2CES1HSD17B10GPR84PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4041186-A | ADJUVANTS | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1977-08-09 | — | — | US | claimed |
| US-4007287-A | Flavoring with (allyl)(2-methyl-3-furyl) sulfide | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1977-02-08 | — | — | US | claimed |
| WO-2009136965-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | SEQUELLA, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281054-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | SEQUELLA, INC. | 2009-11-12 | — | — | US | disclosed |
| US-20090149444-A1 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2009-06-11 | — | — | US | disclosed |
| US-7514475-B2 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2009-04-07 | — | — | US | disclosed |
| US-7504437-B2 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-7504393-B2 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-20080255095-A1 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| EP-1206937-B1 | NITROIMIDAZOLE EXTERNAL PREPARATIONS FOR THE TREATMENT OF ATOPIC DERMATITIS | SHOEI CO LTD (JP) | 2008-01-23 | — | — | EP | disclosed |
| EP-1362844-B1 | BENZYLAMINE ANALOGUE | BTG INT LTD (GB) | 2007-12-05 | — | — | EP | disclosed |
| EP-1276391-A1 | ETHYL 4-(THIOACETOXY)BUTYRATE AS A FLAVORING AGENT AND METHODS FOR PREPARING AND USING SAME | Bush Boake Allen Inc. (US) | 2003-01-22 | — | — | EP | disclosed |
| US-6472384-B1 | Antimicrobial compounds | SANKYO COMPANY, LIMITED (JP) | 2002-10-29 | — | — | US | disclosed |
| US-20020090435-A1 | Ethyl 4-(thioacetoxy)butyrate as a flavoring agent and methods for preparing and using same | BUSH BOAKE ALLEN INC. | 2002-07-11 | — | — | US | disclosed |
| EP-1206937-A1 | NITROIMIDAZOLE EXTERNAL PREPARATIONS FOR DERMATOSIS | SHOEI CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001076389-A1 | ETHYL 4-(THIOACETOXY)BUTYRATE AS A FLAVORING AGENT AND METHODS FOR PREPARING AND USING SAME | BUSH BOAKE ALLEN INC. (US) | 2001-10-18 | — | — | WO | disclosed |
| EP-1095947-A1 | NOVEL ANTIBACTERIAL COMPOUNDS | Sankyo Company Limited (JP) | 2001-05-02 | — | — | EP | disclosed |
| US-4041186-A | ADJUVANTS | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1977-08-09 | — | — | US | disclosed |
| US-4007287-A | Flavoring with (allyl)(2-methyl-3-furyl) sulfide | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1977-02-08 | — | — | US | disclosed |
| US-3988510-A | 3-Furyl sulfides and foodstuff flavor compositions comprising same | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281054-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | TTPA, PHOSPHO1, CAPG | CES2 1009/4885CES1 198/4885HSD17B10 2158/4885 |
| US-20090149444-A1 | Benzylamine analogues | HTR4, DRD4, SLC6A4 | CES2 262/4885CES1 582/4885HSD17B10 392/4885 |
| US-20080255095-A1 | Benzylamine analogues | NR4A3, NAT1, HRH4 | CES2 1842/4885CES1 2701/4885HSD17B10 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.